FDA Approves Ogsiveo (nirogacestat) for Adults with Desmoid Tumors

STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news